Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis.

When adalimumab is used in children, especially in the first 3 months of treatment, in addition to the AEs recorded in the drug package insert, close attention should be paid to the new potential AEs off-label to ensure the safety of adalimumab in children.